Kattamis, Antonis

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia

Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine

Hemoglobinopathies and Related DisordersCRISPR and Genetic Engineering

Cited by 1,962

A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia.

Cappellini, M. D., Viprakasit, V., Taher, A. T., Georgiev, P., Kuo, K. H. M., Coates, T., Voskaridou, E., Liew, H.-K., Pazgal-Kobrowski, I., Forni, G. L., et al. (2020) · New England Journal of Medicine

Hemoglobinopathies and Related DisordersBlood transfusion and management

Cited by 332

Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Locatelli, F., Lang, P., Wall, D., Meisel, R., Corbacioglu, S., Li, A. M., de la Fuente, J., Shah, A. J., Carpenter, B., Kwiatkowski, J. L., et al. (2024) · New England Journal of Medicine

Hemoglobinopathies and Related DisordersVirus-based gene therapy research

Cited by 253

Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials

Maggio, A., Filosa, A., Vitrano, A., Aloj, G., Kattamis, A., Ceci, A., Fucharoen, S., Cianciulli, P., Grady, R. W., Prossomariti, L., et al. (2011) · Blood Cells, Molecules, and Diseases

Hemoglobinopathies and Related DisordersIron Metabolism and Disorders

Cited by 65

Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells

Frangoul, H., Bobruff, Y., Cappellini, M. D., Corbacioglu, S., Fernandez, C. M., de la Fuente, J., Grupp, S. A., Handgretinger, R., Ho, T. W., Imren, S., et al. (2020) · Blood

Hemoglobinopathies and Related DisordersVirus-based gene therapy research

Cited by 54